Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 156

1.

Twelve months of electronic monitoring (MEMS®) in the Swedish COAST-study: a comparison of methods for the measurement of adherence in schizophrenia.

Brain C, Sameby B, Allerby K, Lindström E, Eberhard J, Burns T, Waern M.

Eur Neuropsychopharmacol. 2014 Feb;24(2):215-22. doi: 10.1016/j.euroneuro.2013.11.013. Epub 2013 Dec 4.

PMID:
24359935
2.

Drug attitude and other predictors of medication adherence in schizophrenia: 12 months of electronic monitoring (MEMS(®)) in the Swedish COAST-study.

Brain C, Allerby K, Sameby B, Quinlan P, Joas E, Karilampi U, Lindström E, Eberhard J, Burns T, Waern M.

Eur Neuropsychopharmacol. 2013 Dec;23(12):1754-62. doi: 10.1016/j.euroneuro.2013.09.001. Epub 2013 Sep 19.

PMID:
24091164
3.

Symptom severity and attitudes toward medication: impacts on adherence in outpatients with schizophrenia.

Yang J, Ko YH, Paik JW, Lee MS, Han C, Joe SH, Jung IK, Jung HG, Kim SH.

Schizophr Res. 2012 Feb;134(2-3):226-31. doi: 10.1016/j.schres.2011.11.008. Epub 2011 Nov 30.

PMID:
22133906
4.

Stigma, discrimination and medication adherence in schizophrenia: results from the Swedish COAST study.

Brain C, Sameby B, Allerby K, Quinlan P, Joas E, Lindström E, Burns T, Waern M.

Psychiatry Res. 2014 Dec 30;220(3):811-7.

PMID:
25457284
5.

Antipsychotic treatment dosing profile in patients with schizophrenia evaluated with electronic monitoring (MEMS®).

Acosta FJ, Ramallo-Fariña Y, Bosch E, Mayans T, Rodríguez CJ, Caravaca A.

Schizophr Res. 2013 May;146(1-3):196-200. doi: 10.1016/j.schres.2013.02.016. Epub 2013 Mar 7.

PMID:
23474024
6.

A comparison of electronic monitoring vs. clinician rating of antipsychotic adherence in outpatients with schizophrenia.

Byerly M, Fisher R, Whatley K, Holland R, Varghese F, Carmody T, Magouirk B, Rush AJ.

Psychiatry Res. 2005 Feb 28;133(2-3):129-33.

PMID:
15740989
7.

A comparison study of multiple measures of adherence to antipsychotic medication in first-episode psychosis.

Cassidy CM, Rabinovitch M, Schmitz N, Joober R, Malla A.

J Clin Psychopharmacol. 2010 Feb;30(1):64-7. doi: 10.1097/JCP.0b013e3181ca03df.

PMID:
20075650
8.

Evaluation of subjective treatment satisfaction with antipsychotics in schizophrenia patients.

Fujikawa M, Togo T, Yoshimi A, Fujita J, Nomoto M, Kamijo A, Amagai T, Uchikado H, Katsuse O, Hosojima H, Sakura Y, Furusho R, Suda A, Yamaguchi T, Hori T, Kamada A, Kondo T, Ito M, Odawara T, Hirayasu Y.

Prog Neuropsychopharmacol Biol Psychiatry. 2008 Apr 1;32(3):755-60. doi: 10.1016/j.pnpbp.2007.12.002. Epub 2007 Dec 14.

PMID:
18226436
9.
10.

Relationships among subjective and objective measures of adherence to oral antipsychotic medications.

Velligan DI, Wang M, Diamond P, Glahn DC, Castillo D, Bendle S, Lam YW, Ereshefsky L, Miller AL.

Psychiatr Serv. 2007 Sep;58(9):1187-92.

PMID:
17766564
11.

Assessing medication adherence by pill count and electronic monitoring in the African American Study of Kidney Disease and Hypertension (AASK) Pilot Study.

Lee JY, Kusek JW, Greene PG, Bernhard S, Norris K, Smith D, Wilkening B, Wright JT Jr.

Am J Hypertens. 1996 Aug;9(8):719-25.

PMID:
8862216
12.

Adherence to treatment and therapeutic strategies in schizophrenic patients: the ADHERE study.

Gutiérrez-Casares JR, Cañas F, Rodríguez-Morales A, Hidalgo-Borrajo R, Alonso-Escolano D.

CNS Spectr. 2010 May;15(5):327-37.

PMID:
20448523
13.

[Relationships between insight and medication adherence in subjects with psychosis].

Droulout T, Liraud F, Verdoux H.

Encephale. 2003 Sep-Oct;29(5):430-7. French.

PMID:
14615692
14.

The use of electronic monitoring (MEMS) to evaluate antipsychotic compliance in outpatients with schizophrenia.

Remington G, Kwon J, Collins A, Laporte D, Mann S, Christensen B.

Schizophr Res. 2007 Feb;90(1-3):229-37. Epub 2007 Jan 8.

PMID:
17208414
15.

Validity of electronically monitored medication adherence and conventional adherence measures in schizophrenia.

Byerly MJ, Thompson A, Carmody T, Bugno R, Erwin T, Kashner M, Rush AJ.

Psychiatr Serv. 2007 Jun;58(6):844-7.

PMID:
17535946
16.

[Rationale for the use of long-acting injectable risperidone: a survey of French psychiatrists].

Misdrahi D, Delgado A, Bouju S, Comet D, Chiariny JF.

Encephale. 2013 May;39 Suppl 1:S8-14. doi: 10.1016/j.encep.2012.03.005. Epub 2013 Mar 28. French.

PMID:
23541914
17.
18.

Should full adherence be a necessary goal in schizophrenia? Full versus non-full adherence to antipsychotic treatment.

Acosta FJ, Ramallo-Fariña Y, Siris SG.

Compr Psychiatry. 2014 Jan;55(1):33-9. doi: 10.1016/j.comppsych.2013.09.005. Epub 2013 Oct 8.

PMID:
24183886
19.

Plasma prolactin and central D2 receptor occupancy in antipsychotic drug-treated patients.

Nordström AL, Farde L.

J Clin Psychopharmacol. 1998 Aug;18(4):305-10.

PMID:
9690696
20.

Comparison of patient and clinician perspectives in the assessment of antipsychotic medication adherence.

Barbui C, Kikkert M, Mazzi MA, Becker T, Bindman J, Schene A, Nosè M, Helm H, Thornicroft G, Tansella M.

Psychopathology. 2009;42(5):311-7. doi: 10.1159/000232973. Epub 2009 Aug 11.

PMID:
19672133

Supplemental Content

Support Center